Eli Lilly Bolsters Genetic Medicine Pipeline With $3.2 Billion Kelonia Therapeutics Acquisition INDIANAPOLIS — In a decisive move to dominate the next frontier of oncology, Eli Lilly has announced the acquisition of Kelonia Therapeutics for $3.2 billion, signaling a massive bet on the future of internal genetic reprogramming. The deal secures a promising in vivo … Read more
FDA Approves Foundayo: A New Oral Weight Loss Option Emerges In a significant development for obesity treatment, the Food and Drug Administration (FDA) has granted approval to Foundayo, an oral formulation of the GLP-1 receptor agonist, semaglutide. This marks a pivotal moment, offering a convenient alternative to injectable weight loss medications and sparking considerable interest … Read more
Eli Lilly’s Foundayo Receives FDA Approval, Intensifying Competition in Weight Loss Medications In a significant development for individuals managing obesity and related health conditions, the Food and Drug Administration (FDA) has granted approval to Eli Lilly’s Foundayo (orforglipron), an oral glucagon-like peptide-1 (GLP-1) receptor agonist. This approval arrives approximately three months after Novo Nordisk introduced … Read more
The Rise of Weight-Loss Injections: Benefits, Risks, and the Impact on Food Industry Giants A new wave of injectable medications designed to aid weight loss is rapidly gaining global traction, prompting both excitement and concern. These drugs, often referred to as “slimming needles,” are demonstrating a significant impact on appetite, with studies indicating an average … Read more
Eli Lilly Invests $100 Million in Inflammation Drug Rights from CSL In a significant move signaling heightened competition within the burgeoning field of inflammation-targeted therapies, Eli Lilly and Company has secured rights to develop and commercialize clazakizumab, an IL-6-blocking antibody, from CSL Limited for $100 million upfront. This strategic acquisition positions Lilly to challenge established … Read more
Eli Lilly’s Ascent: Navigating Valuation Amidst GLP-1 Revolution and Future Growth Eli Lilly (LLY) is experiencing a period of intense scrutiny and remarkable growth, fueled by groundbreaking advancements in glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and diabetes treatment. Recent trading has been choppy, reflecting investor attempts to assess the company’s valuation in light of … Read more
Novo Nordisk’s Wegovy Pill: Price War Ignites in Weight Loss Market A significant shift is underway in the rapidly expanding weight loss medication market. Novo Nordisk is strategically positioning its newly approved Wegovy pill with a direct-to-patient price point lower than anticipated, directly challenging Eli Lilly’s forthcoming oral obesity treatment, orforglipron. This move signals a … Read more